Clinical Trials Directory

Trials / Completed

CompletedNCT05569915

Project QueST 2023: Queer Survivors of Trauma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
131 (actual)
Sponsor
Syracuse University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking.

Detailed description

This study aims to provide a novel method for adapting and testing evidence-based expressive writing (EW) treatments for trauma-exposed sexual minority women (SMW) and gender diverse individuals. The investigators will (1) describe the development and components of the proposed EW treatments, (2) discuss our plan for evaluating acceptability and feasibility of the proposed study, (3) identify steps for characterizing preliminary efficacy of EW treatments in reducing PTSD symptom severity and hazardous drinking levels compared to control, and (4) highlight our strategy for preliminarily evaluating mediators and moderators of treatment efficacy.

Conditions

Interventions

TypeNameDescription
BEHAVIORALTrauma Expressive WritingParticipants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
BEHAVIORALStigma Expressive WritingParticipants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
BEHAVIORALControlParticipants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.

Timeline

Start date
2023-06-01
Primary completion
2024-11-30
Completion
2024-11-30
First posted
2022-10-06
Last updated
2026-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05569915. Inclusion in this directory is not an endorsement.